
This phase I trial evaluated a zzso short-term infusion of zzso zzso following oral zzso zzso and zzso zzso zzso Thirteen patients with zzso cancer received 30 cycles of zzso Plasma monitoring demonstrated a zzso increase in peak plasma levels of zzso through the range of dose levels, from zzso zzso zzso zzso at the zzso zzso dose of zzso to zzso zzso zzso zzso at the zzso zzso zzso While zzso did not zzso the usual clinical zzso of zzso plus zzso an unexpected finding of symptomatic zzso during the zzso infusion was the zzso toxicity in this zzso One partial response was observed in a previously zzso patient with zzso zzso zzso The zzso tolerated dose of zzso zzso zzso over 2 zzso is recommended for future phase II evaluation of this novel zzso 

